Literature DB >> 10897147

Characterization of neuronal migration disorders in neocortical structures: loss or preservation of inhibitory interneurons?

P Schwarz1, C C Stichel, H J Luhmann.   

Abstract

PURPOSE: Neuronal migration disorders (NMD) are often associated with therapy-resistant epilepsy. In human cerebral cortex, this hyperexcitability has been correlated with a loss of inhibitory interneurons. We used a rat model of focal cortical NMD (microgyria) to determine whether the expression of epileptiform activity in this model coincides with a decrease in inhibitory interneurons.
METHODS: In 2-to 4-month-old rats, the density of interneurons immunoreactive for gamma-aminobutyric acid (GABA), calbindin, and parvalbumin was determined in fronto-parietal cortex in nine 200-microm-wide sectors located up to 2.5 mm lateral and 2.0 mm medial from the lesion center in primary parietal cortex (Par1). Quantitative measurements in homotopic areas of age-matched sham-operated rats served as controls.
RESULTS: The freeze lesion performed in newborn rat cortex resulted in adult rats with a microgyrus extending in a rostro-caudal direction from frontal to occipital cortex. The density of GABA-and parvalbumin-positive neurons in fronto-parietal cortex was not significantly different between lesioned and control animals. Only the density of calbindin-immunoreactive neurons located 1.0 mm lateral and 0.5 mm medial from the lesion was significantly (Student t test, p < 0.05) larger in freeze-lesioned rats (5,817 +/- 562 and 6,400 +/- 795 cells per mm3, respectively; n = 12) compared with measurements in homotopic regions in Par1 cortex of controls (4,507 +/- 281 and 4, 061 +/- 319 cells per mm3, respectively; n = 5).
CONCLUSIONS: The previously reported widespread functional changes in this model of cortical NMD are not related to a general loss of inhibitory interneurons. Other factors, such as a decrease in GABA receptor density, modifications in GABAA receptor subunit composition, or alterations in the excitatory network, e.g., an increase in the density of calbindin-immunoreactive pyramidal cells, more likely contribute to the global disinhibition and widespread expression of pathophysiological activity in this model of cortical NMD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897147     DOI: 10.1111/j.1528-1157.2000.tb00243.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

1.  Initiation of epileptiform activity in a rat model of periventricular nodular heterotopia.

Authors:  Naranzogt Tschuluun; H Jürgen Wenzel; Emily T Doisy; Philip A Schwartzkroin
Journal:  Epilepsia       Date:  2011-09-20       Impact factor: 5.864

2.  Enhanced infragranular and supragranular synaptic input onto layer 5 pyramidal neurons in a rat model of cortical dysplasia.

Authors:  Julia Brill; John R Huguenard
Journal:  Cereb Cortex       Date:  2010-03-25       Impact factor: 5.357

3.  REORGANIZATION OF BARREL CIRCUITS LEADS TO THALAMICALLY-EVOKED CORTICAL EPILEPTIFORM ACTIVITY.

Authors:  Qian-Quan Sun; John R Huguenard; David A Prince
Journal:  Thalamus Relat Syst       Date:  2005-12

4.  Excitatory and inhibitory synaptic connectivity to layer V fast-spiking interneurons in the freeze lesion model of cortical microgyria.

Authors:  Xiaoming Jin; Kewen Jiang; David A Prince
Journal:  J Neurophysiol       Date:  2014-07-02       Impact factor: 2.714

5.  Enhanced responses to somatostatin interneuron activation in developmentally malformed cortex.

Authors:  Nicole B Ekanem; Laura K Reed; Nicole Weston; Kimberle M Jacobs
Journal:  Epilepsia Open       Date:  2019-03-18

6.  Circuit Mechanisms Underlying Epileptogenesis in a Mouse Model of Focal Cortical Malformation.

Authors:  Weiguo Yang; Anthony Williams; Qian-Quan Sun
Journal:  Curr Biol       Date:  2020-11-05       Impact factor: 10.834

7.  Atypical febrile seizures, mesial temporal lobe epilepsy, and dual pathology.

Authors:  Nathalie T Sanon; Sébastien Desgent; Lionel Carmant
Journal:  Epilepsy Res Treat       Date:  2012-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.